Sei Investments Co. Sells 45,687 Shares of Amgen, Inc. (AMGN)
Sei Investments Co. cut its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 12.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 314,524 shares of the medical research company’s stock after selling 45,687 shares during the quarter. Sei Investments Co.’s holdings in Amgen were worth $58,619,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Courier Capital LLC grew its holdings in shares of Amgen by 185.1% during the third quarter. Courier Capital LLC now owns 50,989 shares of the medical research company’s stock valued at $9,507,000 after purchasing an additional 33,102 shares during the last quarter. FDx Advisors Inc. grew its holdings in Amgen by 2.8% in the 3rd quarter. FDx Advisors Inc. now owns 52,326 shares of the medical research company’s stock worth $9,756,000 after buying an additional 1,443 shares in the last quarter. Alpha Omega Wealth Management LLC grew its holdings in Amgen by 125.9% in the 3rd quarter. Alpha Omega Wealth Management LLC now owns 1,412 shares of the medical research company’s stock worth $263,000 after buying an additional 787 shares in the last quarter. Alps Advisors Inc. grew its holdings in Amgen by 7.1% in the 3rd quarter. Alps Advisors Inc. now owns 5,249 shares of the medical research company’s stock worth $979,000 after buying an additional 349 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in Amgen in the 3rd quarter worth approximately $35,379,000. 78.46% of the stock is owned by institutional investors.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the sale, the executive vice president now owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,050 shares of company stock valued at $1,225,765. 0.19% of the stock is currently owned by corporate insiders.
A number of equities analysts recently issued reports on AMGN shares. BMO Capital Markets reissued a “hold” rating and issued a $199.00 price objective on shares of Amgen in a report on Monday, September 25th. Jefferies Group reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Monday, September 25th. Mizuho reissued a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a report on Thursday, September 28th. Credit Suisse Group reissued a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Bank of America increased their price objective on Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $190.15.
Amgen, Inc. (AMGN) opened at $185.04 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The stock has a market capitalization of $134,320.00, a price-to-earnings ratio of 16.72, a price-to-earnings-growth ratio of 2.60 and a beta of 1.36. Amgen, Inc. has a one year low of $150.38 and a one year high of $191.10.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s quarterly revenue was down .7% on a year-over-year basis. During the same period last year, the company posted $3.02 EPS. equities research analysts predict that Amgen, Inc. will post 12.71 earnings per share for the current year.
Amgen announced that its Board of Directors has approved a share repurchase plan on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 41.55%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with Analyst Ratings Network's FREE daily email newsletter.